Ipsen and Servier announce initial Phase IIIII clinical data evaluating investigational liposomal irinotecan ONIVYDE as a secondline treatment for small cell lung cancer SCLC at the IASLC 2019 World Conference on Lung Cancer

Ipsen and Servier announce initial Phase II/III clinical data evaluating investigational liposomal irinotecan (ONIVYDE) as a second-line treatment for small cell lung cancer (SCLC) at the IASLC 2019 World Conference on Lung Cancer

44% of patients achieved a response and nearly half (48%) maintained disease control at week 12 (efficacy as secondary endpoint) Treatment emergent adverse events Grade 3 or higher were reported b...

More From BioPortfolio on "Ipsen and Servier announce initial Phase II/III clinical data evaluating investigational liposomal irinotecan (ONIVYDE) as a second-line treatment for small cell lung cancer (SCLC) at the IASLC 2019 World Conference on Lung Cancer"